All News

An expert discussion with JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program of elinzanetant for moderate-to-severe VMS.

Cologuard Plus bests its previous iteration and demonstrates greater sensitivity and specificity for any CRC relative to fecal immunochemical tests.

Help young patients with migraine (and their parents) get and stay prepared for the shift from home to college with this migraine survival kit checklist.

Having a PCP is linked to higher rates of screening colonoscopy and improved overall survival. Review these 12 facts about CRC and share them with your patients.

Breast cancer will claim the lives of more than 42 000 women in 2024. The primary care clinician's role as advocate for screening mammography can not be overemphasized.

Your daily dose of the clinical news you may have missed.

The use of visual imaging to detect atherosclerosis at its earliest stages and to quantify the burden enhances predictive value of traditional risk assessment tools.

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

Your daily dose of the clinical news you may have missed.

A 14% increase in the rates of primary care safety planning within 2 weeks of a negative screening was associated 25% drop in the rate of attempted suicides.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program evaluating elinzanetant for menopausal VMS, discusses how non-hormonal therapy differs from HRT.

Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Telehealth offers convenience, saves time, and offers other benefits over office visits, but many people don't even know it's available to them, a new survey found.

Use of menopausal hormone therapy decreased from nearly 27% to 5% among postmenopausal women between 1999 and 2020, according to new research.

Are your patients asking about Ozempic and other GLP-1RAs? Are you prescribing it? Take our quick survey.